The exploratory analysis of biomarkers suggests that the functional profile of T cells and the spatial distribution of CD8+ and PD-L1+ cells better stratify dMMR/MSI-H tumor candidates for anti-PD-1 therapies. The gene discussed is CD274; the disease is neoplasm.